Authors

Ursula Matulonis, MD, Dana-Farber Cancer Institute

Urszula Sobol, MD

Latest:

Mom-Doctor Versus Doctor-Mom

I am still juggling tasks as I try to balance my life at home and life at work.

US Oncology Research

Latest:

US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and Exposition

Top researchers will present abstracts on latest clinical research advancing cancer treatment options.

Utkarsh Acharya, DO

Latest:

In My Humble Opinion: Advice From a Second-Year Fellow

After having devoted the last decade to countless hours in medical school and internal medicine training, you have arrived on the final path of your ultimate career destination.

Latest:

Dr. Sahai on Sequencing Strategies in Metastatic Pancreatic Cancer

Vaibhav Sahai, MBBS, assistant professor of medicine at the University of Michigan, discusses sequencing strategies in metastatic pancreatic cancer.

Vaishalee Kenkre, MD, Walter Longo, MD

Latest:

Novel T-Cell Engineering Strategy Aims to Reduce GVHD in Lymphoma Transplantations

This pilot trial is the first of its type to investigate T cell receptor alpha/beta-depleted and CD19-depleted haploidentical stem cell grafts in relapsed/refractory lymphoma patients.

Valentin Goede, MD

Latest:

Dr. Goede on Obinutuzumab Versus Rituximab in CLL

Valentin Goede, MD, from the University Hospital Cologne, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia with comorbidities.

Vali A. Papadimitrakopoulou, MD, The University of Texas MD Anderson Cancer Center

Vamsidhar Velcheti, MD

Latest:

Looking Ahead: Treatment Advancements and Multidisciplinary Perspectives on the Future of Early-Stage NSCLC Care

Panelists discuss how medical professionals envision the future of early-stage non–small cell lung cancer (NSCLC) treatment evolving through the integration of novel therapies, predictive biomarkers, and personalized strategies to address current gaps in care, emphasizing the need for continued research to optimize outcomes and tailor interventions in resectable disease.

Vamsidhar Velcheti, MD, FACP

Latest:

Dr. Velcheti on the Importance of Real-World Data in NSCLC

Vamsidhar Velcheti, MD, discusses the importance of real-world data for patients with non–small cell lung cancer.

Van K. Morris, MD

Van Karlyle Morris, MD, is an associate professor in the Department of Gastrointestinal (GI) Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center

Latest:

Dr Morris on the Clinical Benefit With Nivolumab Plus Ipilimumab Across dMMR/MSI-H mCRC Subgroups

Van Karlyle Morris, MD, discusses the efficacy of nivolumab plus ipilimumab according to stratification factors in dMMR/MSI-H mCRC.

Vanessa Caceres

Latest:

Experts Discuss Immunotherapy's Potential in Neuro-Oncology

Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.

Vassiliki A. Papadimitrakopoulou, MD

Latest:

Dr. Papadimitrakopoulou on Implications of the NILE Trial in NSCLC

Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the implications of the NILE trial in non–small cell lung cancer (NSCLC).

Vassiliki A. Papadimitrakopoulou, MD, University of Texas MD Anderson Cancer Center

Vassiliki Liana Tsikitis, MD

Latest:

Colorectal Cancer: A Review

Colorectal cancer is the third most common type of cancer diagnosed in the United States and is the third most common cause of cancer-related death.

Vassiliki Papadimitrakopoulou, MD

Latest:

Dr. Papadimitrakopoulou on Biomarker-Driven Clinical Trials in NSCLC

Vassiliki Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses biomarker-driven clinical trials in non–small cell lung cancer.